Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous anti-GPRC5D-CAR-4-1BB-expressing T cells MCARH109

A preparation of autologous T lymphocytes that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D) and the co-stimulatory domain 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-GPRC5D-CAR-4-1BB-expressing T cells MCARH109 specifically recognize and induce selective toxicity in GPRC5D-expressing tumor cells. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation.
Synonym:autologous anti-GPRC5D CAR T cells MCARH109
autologous anti-GPRC5D CAR-T cells MCARH109
autologous GPRC5D-targeted CAR T cells MCARH109
Code name:MCARH 109
MCARH-109
MCARH109
Search NCI's Drug Dictionary